TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

Adoptive transfer of T cells gene-engineered with antigen-specific T cell receptors (TCRs) has proven its feasibility and therapeutic potential in the treatment of malignant tumors. To ensure further clinical development of TCR gene therapy, it is necessary to target immunogenic epitopes that are related to oncogenesis and selectively expressed by tumor tissue, and implement strategies that result in optimal T cell fitness. In addition, in particular for the treatment of solid tumors, it is equally necessary to include strategies that counteract the immune-suppressive nature of the tumor micro-environment. Here, we will provide an overview of the current status of TCR gene therapy, and redefine the following three challenges of improvement: “choice of target antigen”; “fitness of T cells”; and “sensitization of tumor milieu.” We will categorize and discuss potential strategies to address each of these challenges, and argue that advancement of clinical TCR gene therapy critically depends on developments toward each of the three challenges.

• Publication year

  2013

• Venue

  Frontiers in Immunology

• Publication date

  2013-11-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fimmu.2013.00363PMID 24265631PMCID 3821161
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells

  2013cited by this paper
• Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• SHP-1 phosphatase activity counteracts increased T cell receptor affinity.

  2013cited by this paper
• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

  2013cited by this paper
• IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner

  2013cited by this paper
• Recruitment of monocytes/macrophages in different tumor microenvironments.

  2013cited by this paper
• Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

  2013cited by this paper
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013cited by this paper
• Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease.

  2013cited by this paper
• Posttranscriptional control of T cell effector function by aerobic glycolysis.

  2013cited by this paper
• Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

  2013cited by this paper
• Fas expression by tumor stroma is required for cancer eradication

  2013cited by this paper
• Cognate antigen directs CD8+ T cell migration to vascularized transplants.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

  2013cited by this paper
• IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.

  2013cited by this paper
• Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

  2013cited by this paper
• β‐Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid‐derived suppressor cells

  2013cited by this paper
• Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells

  2012cited by this paper
• Ovarian cancer progression is controlled by phenotypic changes in dendritic cells

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies

  2012cited by this paper
• Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

  2012cited by this paper
• Adoptive Transfer of Cytotoxic T Lymphocytes Targeting Two Different Antigens Limits Antigen Loss and Tumor Escape

  2012cited by this paper
• NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine

  2012cited by this paper
• Helper T cell diversity and plasticity.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

  2012cited by this paper
• Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting

  2012cited by this paper
• The cancer antigenome

  2012cited by this paper
• Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Tumor microenvironment and lymphocyte infiltration

  2012cited by this paper
• Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.

  2012cited by this paper
• Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells

  2012cited by this paper
• Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma

  2012cited by this paper
• Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma

  2012cited by this paper
• Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

  2012cited by this paper
• Intratumoral TNFα improves immunotherapy

  2012cited by this paper
• Increased Frequency of Suppressive Regulatory T Cells and T Cell-Mediated Antigen Loss Results in Murine Melanoma Recurrence

  2012cited by this paper
• This information is current as Proteasomes Tumor Antigens by Intermediate Analysis of the Processing of Seven Human Parmentier

  2012cited by this paper
• High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment

  2012cited by this paper
• Paths to stemness: building the ultimate antitumour T cell

  2012cited by this paper
• Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

  2011cited by this paper
• Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

  2011cited by this paper
• Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• Combination of targeted therapy and immunotherapy in melanoma

  2011cited by this paper
• An antigenic peptide produced by reverse splicing and double asparagine deamidation

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Exploring the Genomes of Cancer Cells: Progress and Promise

  2011cited by this paper
• A human memory T-cell subset with stem cell-like properties

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin

  2011cited by this paper
• The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells

  2011cited by this paper
• Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer.

  2011cited by this paper
• T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

  2011cited by this paper
• Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

  2011cited by this paper
• Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

  2011cited by this paper
• Treating cancer with genetically engineered T cells.

  2011cited by this paper
• IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.

  2011influential reference
• CD3 limits the efficacy of TCR gene therapy in vivo.

  2011cited by this paper
• Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.

  2011cited by this paper
• Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

  2011cited by this paper
• Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

  2011cited by this paper
• Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis

  2011cited by this paper
• Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8+ T Cells

  2011cited by this paper
• Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• Expression of tumour-specific antigens underlies cancer immunoediting

  2011cited by this paper
• T cell receptor fused to CD3ζ: Transmembrane domain of CD3ζ prevents TCR mis-pairing, whereas complete CD3ζ directs functional TCR expression

  2011cited by this paper
• T cell exhaustion

  2011cited by this paper
• Th17 cells are long lived and retain a stem cell-like molecular signature.

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

  2011cited by this paper
• Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

  2011cited by this paper
• Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains

  2011cited by this paper
• Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

  2010cited by this paper
• Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

  2010cited by this paper
• Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

  2010cited by this paper
• Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Advances in understanding cancer genomes through second-generation sequencing

  2010cited by this paper
• Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function

  2010influential reference
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Minimal Amino Acid Exchange in Human TCR Constant Regions Fosters Improved Function of TCR Gene-Modified T Cells

  2010cited by this paper
• Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

  2010cited by this paper
• T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies

  2010cited by this paper
• Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage.

  2010cited by this paper
• Therapeutic cell engineering using surface-conjugated synthetic nanoparticles

  2010cited by this paper
• Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

  2010cited by this paper
• Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition

  2010cited by this paper

• NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel

  2025cites this paper
• Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment.

  2024cites this paper
• Current and future immunotherapeutic approaches in pancreatic cancer treatment

  2024cites this paper
• Advances in adoptive T-cell therapy for metastatic melanoma.

  2023cites this paper
• T cell receptor binding affinity governs the functional profile of cancer-specific CD8 + T cells

  2023cites this paper
• Immunotherapies against HER2-Positive Breast Cancer

  2023cites this paper
• Microfluidic T Cell Selection by Cellular Avidity

  2022cites this paper
• CAR-T Cells Targeting Immune Checkpoint Pathway Players.

  2022cites this paper
• Combined overexpression of four transcription factors promotes effector T cell dedifferentiation toward early phenotypes

  2022cites this paper
• Safety evaluation of the mouse TCRα - transduced T cell product in preclinical models in vivo and in vitro.

  2022cites this paper
• Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?

  2022cites this paper
• Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements

  2022cites this paper
• miR-150 promotes progressive T cell differentiation via inhibiting FOXP1 and RC3H1.

  2022cites this paper
• Immune-based therapies in penile cancer

  2022cites this paper
• Penile cancer: Updates in systemic therapy

  2022cites this paper
• DES-Tcell is a knowledgebase for exploring immunology-related literature

  2021cites this paper
• Hepatobiliary Cancers and Immunology

  2020cites this paper
• T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope

  2020cites this paper
• Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

  2020cites this paper
• Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

  2020cites this paper
• The Whole Body as the System in Systems Immunology

  2020cites this paper
• Overexpression of early T cell differentiation-specific transcription factors transforms the terminally differentiated effector T cells into less differentiated state.

  2020cites this paper
• Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients

  2019cites this paper
• Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells

  2019cites this paper
• TCR-like antibodies in cancer immunotherapy

  2019cites this paper
• Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy

  2019cites this paper
• Targeting cancers through TCR-peptide/MHC interactions

  2019cites this paper
• Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response

  2019cites this paper
• The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review

  2019cites this paper
• Cellular immunotherapy in multiple myeloma

  2019cites this paper
• Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells

  2019cites this paper
• Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer

  2019cites this paper
• Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens

  2018cites this paper
• Identification of α‐fetoprotein‐specific T‐cell receptors for hepatocellular carcinoma immunotherapy

  2018cites this paper
• IL-2 mediates NK cell proliferation but not hyperactivity

  2018cites this paper
• PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.

  2018cites this paper
• Cancer Immunotherapy Using CAR‐T Cells: From the Research Bench to the Assembly Line

  2018cites this paper
• Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma

  2018cites this paper
• Adoptive cell transfer: new perspective treatment in veterinary oncology

  2018cites this paper
• Assessing T Cell Receptor Affinity and Avidity Against Tumor Antigens

  2018cites this paper
• Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors.

  2017cites this paper
• The risk of breast cancer relapse depends both on tumor extent and biological Main immunoregulatory mechanisms that favor breast cancer development

  2017cites this paper
• [Main immunoregulatory mechanisms that favor breast cancer development].

  2017cites this paper
• Clinical trials of CAR-T cells in China

  2017cites this paper
• Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.

  2017cites this paper
• Delineating the impact of binding-domain affinity and kinetic properties on Chimeric Antigen Receptor T-cell function

  2017influential citation
• Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors

  2017cites this paper
• New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know

  2017cites this paper
• IL-2 mediates NK cell proliferation but not hyperactivity

  2017cites this paper
• T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.

  2017cites this paper
• Is immunotherapy here to stay in multiple myeloma?

  2017cites this paper
• T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk

  2017cites this paper
• TCR-engineered T cells to treat tumors: Seeing but not touching?

  2016cites this paper
• T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF&agr; Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma

  2016cites this paper
• Adoptive Cellular Therapy (ACT) for Cancer Treatment.

  2016influential citation
• Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy

  2016cites this paper
• Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient

  2016cites this paper
• Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.

  2016cites this paper
• Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.

  2016cites this paper
• Combining the strengths of cytotoxic T cells and nanomedicines for cancer immunotherapy

  2016cites this paper
• Combining oncolytic immunotherapies to break tumor resistance

  2016influential citation
• Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes.

  2016cites this paper
• Predictive Biomarkers for Immunotherapy in Melanoma

  2016cites this paper
• 2015 Guidance on cancer immunotherapy development in early-phase clinical studies.

  2015cites this paper
• Charakterisierung Antigen-spezifischer T-Zellen nach Induktion in TCR-humanisierten Mäusen

  2015cites this paper
• Immunotherapy Approaches in Cancer Treatment.

  2015cites this paper
• T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells

  2015cites this paper
• Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity

  2015cites this paper
• Genetically modified T cells in cancer therapy: opportunities and challenges

  2015cites this paper
• Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens

  2015cites this paper
• Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge

  2015cites this paper
• Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer

  2015cites this paper
• Adoptive T-cell therapy: a need for standard immune monitoring.

  2015cites this paper
• Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

  2015cites this paper
• The Quantity of Autocrine IL-2 Governs the Expansion Potential of CD8+ T Cells

  2015cites this paper
• Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice

  2015cites this paper
• 2015 Guidance on cancer immunotherapy development in early‐phase clinical studies

  2015cites this paper
• Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors

  2015cites this paper
• Permissive expansion and homing of adoptively transferred T cells in tumor‐bearing hosts

  2015cites this paper
• Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor

  2015cites this paper
• TCRs Genetically Linked to CD28 and CD3ε Do Not Mispair with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity

  2014influential citation
• Bench, Bedside, Toolbox: T-Cells Deliver on Every Level

  2014cites this paper
• T Cell Receptor-Engineered T Cells to Treat Solid Tumors: T Cell Processing Toward Optimal T Cell Fitness

  2014cites this paper
• To affinity and beyond: Harnessing the T Cell receptor for cancer immunotherapy

  2014cites this paper
• This information is current as Persistence and Anti-Melanoma Activity Chains and Mediate Enhanced T Cell Do Not Mispair with Endogenous TCR ε TCRs Genetically Linked to CD28 and CD3

  2014cites this paper
• Identification of Vβ7.1_H3F7 as a therapeutic gene encoding TCR specific to hepatocellular carcinoma.

  2014cites this paper
• Persistence and Anti-melanoma Activity Chains and Mediate Enhanced T Cell Do Not Mispair with Endogenous Tcr Ε Tcrs Genetically Linked to Cd28 and Cd3

  year unknowncites this paper